When tocilizumab is not available, sarilumab, a human monoclonal antibody targeting IL-6 soluble receptors, which is already approved for rheumatoid arthritis (RA) treatment, represents a valid alternative for IL-6 blockade [9]. The gene discussed is IL6; the disease is rheumatoid arthritis.